Tiragolumab

Generic Name: Tiragolumab

Drug Type: Biotech

CAS Number: 1918185-84-8

Unique Ingredient Identifier: 6XG22YQM2Z

Background: Tiragolumab is under investigation in clinical trial NCT04513925 (A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)).

Clinical Trials

Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection

Phase 2

Terminated

Conditions: Stage II Melanoma

Interventions: Drug: Atezolizumab
Drug: Tiragolumab
Device: Signatera Assay

First Posted Date: 2021-09-28

Last Posted Date: 2024-02-20

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 7

Registration Number: NCT05060003

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer

Phase 2

Active, not recruiting

Conditions: Rectal Neoplasms
Rectal Cancer

Interventions: Radiation: Radiotherapy
Drug: Capecitabine
Drug: Fluorouracil
Drug: Atezolizumab
Drug: Tiragolumab

First Posted Date: 2021-08-17

Last Posted Date: 2025-04-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 58

Registration Number: NCT05009069

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou City, China
🇨🇳
Zhongshan Hospital Fudan University, Shanghai, China

and more 2 locations

Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

Phase 2

Recruiting

Conditions: Non-squamous Non-small-cell Lung Cancer

Interventions: Drug: Tiragolumab
Drug: Atezolizumab
Drug: Bevacizumab

First Posted Date: 2021-07-12

Last Posted Date: 2025-03-24

Lead Sponsor: Georgetown University

Target Recruit Count: 42

Registration Number: NCT04958811

Locations: 🇺🇸
MedStar Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)

Phase 2

Terminated

Conditions: Gastric Cancer
Stomach Neoplasms
Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: Atezolizumab
Drug: Tiragolumab
Drug: Oxaliplatin
Drug: Capecitabine

First Posted Date: 2021-06-21

Last Posted Date: 2024-11-14

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 29

Registration Number: NCT04933227

Locations: 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, China
🇨🇳
Jilin Cancer Hospital, Changchun, China
🇨🇳
Beijing Cancer Hospital, Beijing, China

and more 8 locations

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Phase 1

Recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Inavolisib
Drug: Cetuximab
Drug: Bevacizumab
Drug: Atezolizumab
Drug: SY-5609
Drug: Divarasib
Drug: Tiragolumab
Drug: FOLFOX
Drug: FOLFIRI

First Posted Date: 2021-06-18

Last Posted Date: 2025-05-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 542

Registration Number: NCT04929223

Locations: 🇺🇸
UAB Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

and more 70 locations

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer (NSCLC)

Interventions: Drug: Atezolizumab
Drug: Tiragolumab
Drug: Carboplatin
Drug: Cisplatin
Drug: Pemetrexed
Drug: Gemcitabine
Drug: Paclitaxel

First Posted Date: 2021-04-06

Last Posted Date: 2025-03-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 50

Registration Number: NCT04832854

Locations: 🇪🇸
ICO L'Hospitalet, L Hospitalet De Llobregat, Barcelona, Spain
🇨🇭
Kantonsspital St. Gallen, St. Gallen, Switzerland
🇨🇭
UniversitätsSpital Zürich, Zürich, Switzerland

and more 19 locations

A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

Phase 2

Active, not recruiting

Conditions: Squamous Cell Carcinoma of Head and Neck

Interventions: Drug: Atezolizumab
Drug: Tiragolumab
Drug: Placebo

First Posted Date: 2020-12-14

Last Posted Date: 2025-03-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 123

Registration Number: NCT04665843

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇨🇿
Fakultni nemocnice v Motole, Praha 5, Czechia
🇫🇷
Centre Francois Baclesse, Caen, France

and more 41 locations

Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

Phase 3

Active, not recruiting

Conditions: Small Cell Lung Carcinoma

Interventions: Drug: Tiragolumab
Drug: Atezolizumab
Drug: Carboplatin
Drug: Tiragolumab Matching Placebo
Drug: Etoposide

First Posted Date: 2020-12-14

Last Posted Date: 2025-04-10

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 123

Registration Number: NCT04665856

Locations: 🇨🇳
Beijing Chest Hospital, Beijing, China
🇨🇳
Zhejiang Cancer Hospital, Hangzhou, China
🇨🇳
Beijing Cancer Hospital, Beijing, China

and more 13 locations

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

Phase 2

Completed

Conditions: Advanced Unresectable or Metastatic Solid Malignancy

Interventions: Drug: Entrectinib
Drug: Inavolisib
Drug: Alectinib
Drug: Ipatasertib
Drug: Atezolizumab
Drug: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf
Drug: Pralsetinib
Drug: Investigator's Choice of Chemotherapy
Drug: Trastuzumab Emtansine
Drug: Tucatinib
Drug: Paclitaxel
Drug: Tiragolumab

First Posted Date: 2020-11-17

Last Posted Date: 2025-01-08

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 252

Registration Number: NCT04632992

Locations: 🇺🇸
Sarah Cannon Research Institute / Tennessee Oncology, Chattanooga, Tennessee, United States
🇺🇸
SCRI Oncology Partners, Nashville, Tennessee, United States
🇺🇸
Alaska Oncology and Hematology, Anchorage, Alaska, United States

and more 35 locations

A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer

Phase 2

Active, not recruiting

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: Tiragolumab
Drug: Atezolizumab
Drug: Pemetrexed
Drug: Tiragolumab Matching Placebo
Drug: Carboplatin
Drug: Cisplatin
Drug: Pembrolizumab

First Posted Date: 2020-11-06

Last Posted Date: 2025-03-07

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 542

Registration Number: NCT04619797

Locations: 🇯🇵
Hiroshima University Hospital, Hiroshima, Japan
🇲🇽
ARKE Estudios Clínicos S.A. de C.V., Ciudad de México, Mexico
🇳🇿
Auckland City Hospital, Cancer and Blood Research, Auckland, New Zealand

and more 125 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy